Kristófi R, Eriksson JW. Metformin as an anti-inflammatory agent: a short review. J Endocrinol. 2021;251:R11–22.

Article  PubMed  Google Scholar 

Triggle CR, Mohammed I, Bshesh K, et al. Metformin: Is it a drug for all reasons and diseases? Metabolism. 2022;133: 155223.

Article  CAS  PubMed  Google Scholar 

Tseng CH. Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus. J Crohns Colitis. 2021;15:64–73.

Article  PubMed  Google Scholar 

Allin KH, Jensen CB, Jacobsen RK, et al. Metformin use is not associated with reduced risk of older onset inflammatory bowel disease: a Danish nationwide population-based study. J Gastroenterol. 2022;57:761–9.

Article  CAS  PubMed  Google Scholar 

Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489–526.

Article  PubMed  PubMed Central  Google Scholar 

Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740–51.

Article  PubMed  Google Scholar 

Araki M, Shinzaki S, Yamada T, et al. Age at onset is associated with the seasonal pattern of onset and exacerbation in inflammatory bowel disease. J Gastroenterol. 2017;52:1149–57.

Article  PubMed  Google Scholar 

Amano T, Shinzaki S, Asakura A, et al. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease. Sci Rep. 2022;12:5324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okabayashi S, Yamazaki H, Tominaga K, et al. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther. 2022;55:1569–80.

Article  CAS  PubMed  Google Scholar 

Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091–103.

Article  CAS  PubMed  Google Scholar 

Mimura S, Ando T, Ishiguro K, et al. Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis. Scand J Gastroenterol. 2013;48:1152–9.

Article  CAS  PubMed  Google Scholar 

Pizzoferrato M, Puca P, Ennas S, et al. Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure. World J Gastroenterol. 2022;28:6258–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang PY, Zou H, Lee C, et al. Stapled, Long-acting glucagon-like peptide 2 analog with efficacy in dextran sodium sulfate induced Mouse Colitis models. J Med Chem. 2018;61:3218–23.

Article  CAS  PubMed  Google Scholar 

Villumsen M, Schelde AB, Jimenez-Solem E, et al. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine. 2021;37: 100979.

Article  PubMed  PubMed Central  Google Scholar 

Shinzaki S, Matsuoka K, Tanaka H, et al. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol. 2021;56:560–9.

Article  CAS  PubMed  PubMed Central  Google Scholar